Efficacy and safety of letermovir for cytomegalovirus prophylaxis in thoracic organ transplantation: a systematic review and meta-analysis.

ABSTRACT:

Objective

Letermovir (LTV) is a novel antiviral agent approved for cytomegalovirus (CMV) prophylaxis in high risk allogeneic hematopoietic stem cell transplantation. However, its efficacy and safety in thoracic organ transplant (TOT) recipients remain underexplored. This study systematically evaluates the efficacy and safety of LTV prophylaxis for CMV infection in TOT recipients.

Methods

A systematic search of PubMed, Scopus, Web of Science, Embase, and Cochrane Library was conducted up to February 2025. Studies assessing LTV prophylaxis in adult TOT were included. We performed a single-arm meta-analysis using Open Meta Analyst software and a double-arm meta-analysis with Review Manager. Dichotomous outcomes were pooled as event rates using the fixed-effects model.

Result

SUBMITTER: Aldalati AY 

PROVIDER: S-EPMC12751466 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature